Steroids Added to Dithranol and Narrow Band UVB (UVBnb) in Psoriasis
Information source: University of Zurich
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psoriasis
Intervention: Topical steroids (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Zurich Official(s) and/or principal investigator(s):
Guenther Hofbauer, MD, Leading Physician, Principal Investigator, Affiliation: University Hospital Zurich, Division of Dermatology
Overall contact:
Guenther Hofbauer, MD, Email: hofbauer@usz.ch
Summary
Objective(s):
(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
loss of PASI improvement obtained through the antecedent treatment.
(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).
- Trial with medicinal product
Clinical Details
Official title: DIPSO A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB and Dithranol Combination Treatment of Psoriasis
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Relapse 50% PASI after treatment, time to PASI 75% on treatment
Detailed description:
(i) To assess the effect of adjunctive topical steroids in the combined treatment with UVBnb
and dithranol on the remission time after therapy till a relapse of psoriasis defined as 50%
loss of PASI improvement obtained through the antecedent treatment.
(ii) To assess the impact of adjuvant topical steroids in the combined treatment with UVBnb
and dithranol on the clearing time of psoriasis lesions under therapy (PASI 75).
- Trial with medicinal product
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Moderate to severe psoriasis of the chronic-plaque and / or guttata type
Exclusion criteria:
- Participation in a Goeckerman therapy regimen within 6 months previous to the present
study
Locations and Contacts
Guenther Hofbauer, MD, Email: hofbauer@usz.ch
University Hospital Dermatology Department, Zurich 8091, Switzerland; Recruiting
Martin Glatz, MD, Phone: +41442551111, Email: martin.glatz@usz.ch
Additional Information
Starting date: August 2011
Last updated: January 28, 2013
|
